Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.56 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.54 |
| ▸ | AHCY | P23526 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260398 | 0.89 | ADORA2A (0.66) | ADORA2AADORA3HSP90B1ADORA2BADORA1 | |
| SCHEMBL12935928 | 0.88 | ADORA2A (0.75) | ADORA2AADORA3HSP90B1ADORA2BADORA1 | |
| SCHEMBL260517 | 0.85 | ADORA2A (0.66) | ADORA2AADORA1 | |
| SCHEMBL13913202 | 0.82 | ADORA3 (0.61) | ADORA2AADORA3HSP90B1ADORA2BADORA1 | |
| SCHEMBL260739 | 0.81 | ADORA2A (0.54) | ADORA2AADORA3ADORA1 | |
| SCHEMBL260643 | 0.81 | ADORA2A (0.59) | ADORA2AADORA3HSP90B1ADORA1 | |
| SCHEMBL260637 | 0.81 | ADORA2A (0.56) | ADORA2AADORA1 | |
| SCHEMBL260724 | 0.81 | ADORA2A (0.54) | ADORA2AADORA1 | |
| SCHEMBL260402 | 0.80 | ADORA2A (0.59) | ADORA2AADORA1 | |
| SCHEMBL260646 | 0.80 | ADORA2A (0.53) | ADORA2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133880-B2 | Purine derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | PNP, NUDT1, HPRT1 | ADORA2A 4/4885ADORA3 26/4885HSP90B1 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.